Bayer (BAYN) PT Set at €70.00 by Deutsche Bank

Deutsche Bank set a €70.00 ($81.40) target price on Bayer (FRA:BAYN) in a report issued on Thursday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.

BAYN has been the topic of a number of other reports. Societe Generale set a €65.00 ($75.58) price target on Bayer and gave the company a neutral rating in a research report on Wednesday, March 27th. UBS Group set a €110.00 ($127.91) price target on Bayer and gave the company a buy rating in a research report on Monday, February 4th. DZ Bank reiterated a buy rating on shares of Bayer in a research report on Monday, March 11th. Baader Bank set a €123.00 ($143.02) price target on Bayer and gave the company a buy rating in a research report on Friday, January 18th. Finally, Nord/LB set a €72.00 ($83.72) price target on Bayer and gave the company a neutral rating in a research report on Wednesday, February 27th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of Hold and an average price target of €81.80 ($95.12).

Shares of FRA:BAYN opened at €61.16 ($71.12) on Thursday. Bayer has a fifty-two week low of €91.58 ($106.49) and a fifty-two week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: What is systematic risk?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit